Posters

      Systems toxicology analysis of cardiovascular and respiratory endpoints from Apoe-/- mice showed similar effects after switching to a candidate modified risk tobacco product, THS 2.2, or to smoking cessation

      Phillips, B.; Boue, S.; Vuillaume, G.; Martin, F.; Leroy, P.; Veljkovic, E.; Peitsch, M.; Hoeng, J.

      Conference date
      Mar 23, 2015
      Conference name

      Society of Toxicology (SOT) 2015
      Link to more information
      Topic
      Summary

      Cigarette smoking (CS) is the main risk factor for the development and progression of a series of diseases, including cardiovascular disease (CVD) and chronic obstructive pulmonary disease (COPD). Suitable animal models play an important role in understanding of smoke-induced pathogenesis. This study examined the development of hallmarks of both COPD and CVD in Apoe-/- mice exposed to either CS or to an aerosol from a candidate modified risk tobacco product, the tobacco heating system (THS2.2) over an 8-month period. In addition to chronic exposure regimes, a comparison of exposure cessation or switching to THS2.2 after 2 months of exposure to CS was performed using a battery of assays (physiological, morphological and molecular). Biological interpretation of various endpoints enables to understand the biological effects of cessation/switching as compared to continuous smoking.  

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
      ​
      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.